KalVista Pharmaceuticals, Inc. completed its merger with Chiesi Farmaceutici S.p.A., becoming a wholly owned subsidiary of Parent. The transaction involved a tender offer at $27.00 per share in cash, which was successful with 77.8% of shares validly tendered. Remaining shares were converted into the right to receive the $27.00 merger consideration. The company's common stock was delisted from the Nasdaq Global Market on June 11, 2026. KalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on oral small molecule therapeutics for gastrointestinal diseases.